John‐Michael Sauer

Characterization of a Novel Endocannabinoid, Virodhamine, with Antagonist Activity at the CB1 Receptor

Amy C. Porter, John‐Michael Sauer, Michael D. Knierman et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 610 citations

Medicine, Neurobiology, Pharmacology +10

Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort

Rachel J. Church, Gerd A. Kullak‐Ublick, Jiri Aubrecht et al. · Hepatology · 2018 · 243 citations · Full text

Veterinary Medicine, Pharmacology, Toxicology +17

Disposition and Metabolic Fate of Atomoxetine Hydrochloride: The Role of CYP2D6 in Human Disposition and Metabolism

John‐Michael Sauer, G. Douglas Ponsler, Edward L. Mattiuz et al. · Drug Metabolism and Disposition · 2003 · 151 citations

Medicine, Pharmacokinetics, Pharmacology +16

Atomoxetine Pharmacokinetics in Children and Adolescents with Attention Deficit Hyperactivity Disorder

Jennifer Witcher, Amanda Long, Brian P. Smith et al. · Journal of Child and Adolescent Psychopharmacology · 2003 · 117 citations

Medicine, Pharmacokinetics, Pharmacology +17

Cytotoxicity and genotoxicity of methyleugenol and related congeners — a mechanism of activation for methyleugenol

Jennifer Burkey, John‐Michael Sauer, Charlene A. McQueen et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2000 · 112 citations

Pharmacy, Genetics, Toxicology +12